Gemin X Biotechnologies focused on the discovery and development of novel therapeutics to modulate apoptosis, the body’s natural ability to destroy diseased or damaged cells, in life-threatening diseases. Their lead product was, GX15-070, a small molecule, pan-inhibitor of the Bcl-2 protein family. The company was acquired by Cephalon in April 2011 for $225mm in an all-cash deal with up to $300mm in milestone payments for certain regulatory and sales goals.